Surrogate endpoints of efficacy [electronic resource] / Maurie Markman.Material type: FilmSeries: Henry Stewart talksBiomedical & life sciences collection. Cancer therapy : latest thinking in efficacy and toxicity: Publisher: London : Henry Stewart Talks, 2018Description: 1 online resource (1 streaming video file (33 min.) : color, sound)Subject(s): Antineoplastic agents | Cancer -- Chemotherapy | Cancer -- Treatment -- Evaluation | Clinical trials | Outcome assessment (Medical care) | Antineoplastic Agents -- administration & dosage | Antineoplastic Agents -- therapeutic use | Biomarkers | Clinical Trials as Topic | Endpoint Determination | Goals | Neoplasms -- prevention & control | Neoplasms -- therapy | Treatment OutcomeOnline resources: Click here to access online | Series
Animated audio-visual presentation with synchronized narration.
Title from title frames.
Updated version of a talk first published in 2009.
Contents: Improvement in overall survival must be considered the single most important goal of any new antineoplastic strategy -- Also increasingly recognized that in well-defined settings it is reasonable to employ other objectively measurable endpoints of efficacy such as time to symptomatic disease progression -- The rationale for the use of surrogate or alternative endpoints in cancer clinical trials -- Examples of where such endpoints may be appropriately utilized.
Access restricted to subscribers.
Mode of access: World Wide Web.